Legend Biotech Corporation
NNASDAQ:LEGNCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ingrid Zhang
- Full Time Employees
- 2,900
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2101 Cottontail Lane Bridgewater NJ United States 08873
- IPO Date
- Jun 5, 2020
- CIK
- 0001801198
- Website
- legendbiotech.com
- Similar Companies
- Business
- Legend Biotech Corporation Legend Biotech Corporation (LEGN) is a global commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of cell therapies targeting oncology indications including hematologic malignancies such as multiple myeloma and solid tumors. Founded in 2014 and headquartered in Somerset, New Jersey, the company operates facilities across the United States including Piscataway and a new R&D center in Philadelphia, as well as in Nanjing, China; Dublin, Ireland; and Ghent, Belgium. Its lead product, CARVYKTI (ciltacabtagene autoleucel; cilta-cel), an autologous BCMA-targeted CAR-T therapy developed and commercialized in partnership with Janssen Biotech, Inc., treats relapsed or refractory multiple myeloma and generates primary revenue through license and collaboration agreements predominantly from the United States; the company also advances a pipeline of investigational autologous CAR-T candidates for non-Hodgkin lymphoma, acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, small cell lung, and non-small cell lung cancers, alongside allogeneic CAR-NK, CAR-γδ T, and non-gene-editing CAR technologies. Recent developments include the official opening of a state-of-the-art cell therapy R&D facility in Philadelphia in November 2025, plans to double CARVYKTI manufacturing capacity in 2025 through new sites in Raritan, New Jersey, and Ghent, Belgium under agreements with Janssen and Novartis, a strategic partnership with Novartis announced in 2024 providing $100 million upfront for CAR-T candidates targeting solid tumors via the T-Charge platform with over $1 billion in potential milestones, and a collaboration with Multiply Labs to automate CAR-T manufacturing processes.
Company News
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Legend Biotech Q2 Earnings Call Highlights
Legend Biotech (NASDAQ:LEGN) Shares Gap Down After Analyst Downgrade
Legend Biotech Announces CEO Transition